Researchers at the Massachusetts Institute of Technology have developed a generative AI model that was able to generate novel antibiotic structures from either chemical fragments or de novo, starting from ammonia, methane, water or no starting point at all. In a study that was published online in Cell, the team tested two dozen of more than 10 million structures that were proposed as potential antibiotics by the model.
Researchers from the California Institute of Technology and collaborating institutions have developed a novel HIV vaccine candidate, a new germline-targeting Env SOSIP trimer called 3nv.2, that is designed to elicit antibodies targeting three key epitopes on the HIV envelope protein.
Deficiencies in interferon-stimulated gene 15 (ISG15), a protein that normally regulates the immune response, causes mild but persistent inflammation. However, its absence also provides an unexpected advantage by increasing resistance to viral infections. Inspired by this condition and using mRNA technology, scientists at Columbia University and the Icahn School of Medicine at Mount Sinai have developed a broad-spectrum antiviral platform.
DNA-binding drugs have shown potential against the parasitic disease African trypanosomiasis (sleeping sickness), but they have several disadvantages, such as toxic effects or inability to cross the blood-brain barrier, which may prevent them from treating individuals in which the parasites have entered the central nervous system.
Researchers at the Massachusetts Institute of Technology have developed a generative AI model that was able to generate novel antibiotic structures from either chemical fragments or de novo, starting from ammonia, methane, water or no starting point at all. In a study that was published online in Cell, the team tested two dozen of more than 10 million structures that were proposed as potential antibiotics by the model.
For more than 30 years, the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) worked together to harmonize their evidence-based vaccine schedules. Not anymore.
Avixgen Co. Ltd., a subsidiary of Dx&Vx Co. Ltd., inked a $360 million license agreement with an unidentified U.S.-based biotechnology company, granting the latter rights to its advanced cell penetrating (ACP) peptide drug delivery platform.
CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than $500 million per year over the next three years.
Lifemine Therapeutics Inc. has identified serine/threonine-protein phosphatase 2B (PPP3CC; PP2Bγ; calcineurin) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome (SARS), fungal infections, transplant rejection, and dermatological, respiratory and eye disorders.
Mycobacterium abscessus, a nontuberculous mycobacterium, is a significant cause of chronic pulmonary infections, particularly in individuals with compromised immune systems or structural lung conditions, such as cystic fibrosis.
RSS
